Model 1 (n=3947) | OR (95% CI) | P value |
Nadir CD4 group (cells/µL) | ||
<200 | 1.2 (0.8 to 1.7) | 0.34 |
200–500 | 1.0 (0.8 to 1.3) | 0.98 |
≥500 | Reference | |
Median CD4 group | ||
<200 | 2.1 (1.5 to 3.0) | <0.0001 |
200–500 | 1.3 (1.0 to 1.7) | 0.052 |
≥500 | Reference | |
CD4 trajectory group | ||
Group 1 | 2.6 (1.5 to 4.4) | 0.0004 |
Group 2 | 1.3 (0.8 to 2.0) | 0.24 |
Group 3 | 1.4 (0.9 to 2.0) | 0.13 |
Group 4 | 2.5 (1.4 to 4.3) | 0.0012 |
Group 5 | 1.2 (0.9 to 1.6) | 0.27 |
Group 6 | Reference | |
Model 2 (n=3809) | ||
Nadir CD4 group (cells/µL) | ||
<200 | 1.3 (0.9 to 1.9) | 0.16 |
200–500 | 1.0 (0.8 to 1.4) | 0.74 |
≥500 | Reference | |
Median CD4 group | ||
<200 | 2.3 (1.6 to 3.2) | <0.0001 |
200–500 | 1.3 (1.0 to 1.7) | 0.041 |
≥500 | Reference | |
CD4 trajectory group | ||
Group 1 | 2.9 (1.7 to 5.0) | <0.0001 |
Group 2 | 1.4 (0.9 to 2.2) | 0.15 |
Group 3 | 1.5 (1.0 to 2.2) | 0.066 |
Group 4 | 2.5 (1.4 to 4.5) | 0.0018 |
Group 5 | 1.2 (0.9 to 1.6) | 0.27 |
Group 6 | Reference |
Both models 1 and 2 were controlled for ages at baseline, HIV diagnosis, HAUD, median years of follow-up, gender and HIV risk factors.
HAUD, herpetic anogenital ulcer disease.